NCT02405520CompletedPhase 1
A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years
Jun Zhang0 sites145 target enrollmentStarted: March 26, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 145
- Primary Endpoint
- Measure adverse reactions/events throughout the study
Study Overview
Brief Summary
This phase I clinical study was designed to evaluate the safety and immunogenicity of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 18-55 years of age at enrollment. The study volunteers will receive the 3 different formulations of the novel HPV vaccine or placebo administered intramuscularly according to a 0-1-6 month schedule.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Health people aged between 18 and 55 years.
- •Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations.
- •Written informed consent was obtained from the participants.
- •Able to comply with the requests of the study.
- •Axillary temperature not higher than 37.0°C
- •Men, or non-pregnant women verified by a urine pregnancy test.
Exclusion Criteria
- •Pregnant or breastfeeding or plan to be pregnant within 7 months.
- •Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period.
- •Received immunosuppressed, immunoregulation therapy, or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment.
- •Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine or plan to use within 7 months.
- •Administration of any attenuated live vaccines within 21 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination.
- •Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination.
- •Having the plan to participate another clinical trial during the study period.
- •Received another HPV vaccine.
- •Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, .or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response).
- •History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.
- •Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years.
- •Having serious disease of internal medicine, such as hypertension, cardiac disease, diabetes, hyperthyroidism et al.
- •Diagnosed coagulant function abnormality (i.e., clotting factors absent, clotting hemorrhagic disease, abnormal platelet function) or blood coagulation disorder.
- •Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years.
- •Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or h a tendency to commit suicide.
- •Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent.
Outcomes
Primary Outcomes
Measure adverse reactions/events throughout the study
Time Frame: 10 month
With composite measure: Measure solicited local/systematic adverse reactions within 7 days after each vaccination; Measure unsolicited adverse reactions within 30 days after vaccination; Measure blood, liver and kidney function changes pre- and 2 days post vaccination; Measure serious adverse events occurred throughout the study
Secondary Outcomes
- Measure anti-HPV 6/11 antibody in serum samples at 7 month to evaluate the immunogenicity of the HPV 6/11 vaccine formulations.(7 month)
Investigators
Jun Zhang
Professor
Xiamen University
Similar Trials
Active, not recruiting
Phase 2
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent VaccineCondylomata AcuminataNCT02710851Jun Zhang640
Completed
Phase 1
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected AdultsHIV InfectionsNCT03699241International AIDS Vaccine Initiative61
Completed
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy VolunteersHealthyNCT02309762Fountain Biopharma Inc.54
Completed
Phase 1
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647Cytomegalovirus InfectionNCT05105048ModernaTX, Inc.9
Completed
Phase 1
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese ParticipantsHealthy VolunteerNCT05070312AstraZeneca39